Company intelligence / Profile preview

TopoTarget

Ownership: Private
Employees: ~53
Development stage: Other

Overview

TopoTarget was a Danish biotechnology company specializing in the discovery and development of cancer therapies. Its lead product was belinostat, an HDAC inhibitor developed for hematological cancers and solid tumors. The company also marketed Savene®/Totect™ for anthracycline extravasation injuries. In addition to its own R&D pipeline, it engaged in multiple academic and industry collaborations. In July/August of 2014, TopoTarget merged with BioAlliance Pharma to form Onxeo S.A., ceasing independent operations.

Therapeutic areas: OncologyDermatologyRare Diseases
Modalities: Small moleculesFusion proteinsAntibody-drug conjugates
Industry: Biotech

Partnerships

Spectrum Pharmaceuticals Inc.Multimeric Biotherapeutics Inc.National Cancer InstituteNovartisLundbeck

Beyond the preview

Go deeper on TopoTarget.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TopoTarget.